Cargando…
Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108438/ https://www.ncbi.nlm.nih.gov/pubmed/26417987 http://dx.doi.org/10.1111/jdv.13391 |
| _version_ | 1782467359153324032 |
|---|---|
| author | Hart, C. Vogelhuber, M. Hafner, C. Landthaler, M. Berneburg, M. Haferkamp, S. Herr, W. Reichle, A. |
| author_facet | Hart, C. Vogelhuber, M. Hafner, C. Landthaler, M. Berneburg, M. Haferkamp, S. Herr, W. Reichle, A. |
| author_sort | Hart, C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5108438 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-51084382016-11-16 Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial Hart, C. Vogelhuber, M. Hafner, C. Landthaler, M. Berneburg, M. Haferkamp, S. Herr, W. Reichle, A. J Eur Acad Dermatol Venereol Letters to the Editor John Wiley and Sons Inc. 2015-09-29 2016-11 /pmc/articles/PMC5108438/ /pubmed/26417987 http://dx.doi.org/10.1111/jdv.13391 Text en © 2015 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters to the Editor Hart, C. Vogelhuber, M. Hafner, C. Landthaler, M. Berneburg, M. Haferkamp, S. Herr, W. Reichle, A. Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial |
| title | Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial |
| title_full | Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial |
| title_fullStr | Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial |
| title_full_unstemmed | Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial |
| title_short | Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial |
| title_sort | biomodulatory metronomic therapy in stage iv melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase i trial |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108438/ https://www.ncbi.nlm.nih.gov/pubmed/26417987 http://dx.doi.org/10.1111/jdv.13391 |
| work_keys_str_mv | AT hartc biomodulatorymetronomictherapyinstageivmelanomaiswelltoleratedandmayinduceprolongedprogressionfreesurvivalaphaseitrial AT vogelhuberm biomodulatorymetronomictherapyinstageivmelanomaiswelltoleratedandmayinduceprolongedprogressionfreesurvivalaphaseitrial AT hafnerc biomodulatorymetronomictherapyinstageivmelanomaiswelltoleratedandmayinduceprolongedprogressionfreesurvivalaphaseitrial AT landthalerm biomodulatorymetronomictherapyinstageivmelanomaiswelltoleratedandmayinduceprolongedprogressionfreesurvivalaphaseitrial AT berneburgm biomodulatorymetronomictherapyinstageivmelanomaiswelltoleratedandmayinduceprolongedprogressionfreesurvivalaphaseitrial AT haferkamps biomodulatorymetronomictherapyinstageivmelanomaiswelltoleratedandmayinduceprolongedprogressionfreesurvivalaphaseitrial AT herrw biomodulatorymetronomictherapyinstageivmelanomaiswelltoleratedandmayinduceprolongedprogressionfreesurvivalaphaseitrial AT reichlea biomodulatorymetronomictherapyinstageivmelanomaiswelltoleratedandmayinduceprolongedprogressionfreesurvivalaphaseitrial |